Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Severe Obstructive Sleep Apnea Doubles Risk of Heart Attack Death

XTALKS VITALS NEWS

Sleep Apnea

A recent study published in the American Heart Association’s (AHA) journal, Circulation, found that both moderate and severe forms of sleep apnea were associated with a higher risk of cardiovascular disease.

Share this!

February 9, 2017 | by Sarah Hand, M.Sc.

February is American Heart Month, and according to the National Healthy Sleep Awareness Project, leaving severe obstructive sleep apnea untreated raises an individual’s risk of suffering a fatal heart attack. In order to raise public awareness of this risk, the associations – in partnership with the American Academy of Sleep Medicine (AASM), the Centers for Disease Control and Prevention (CDC) and the Sleep Research Society (SRS) – are launching an ad campaign called “Sleep Apnea Hurts Hearts.”

A recent study published in the American Heart Association’s (AHA) journal, Circulation, found that both moderate and severe forms of sleep apnea were associated with a higher risk of cardiovascular disease. Treatment for sleep apnea often involves the use of a continuous positive airway pressure (CPAP) device.



“Obstructive sleep apnea is a dangerous disease that can severely damage your heart if left untreated,” said Dr. Ronald Chervin, president of the AASM and a spokesperson for the National Healthy Sleep Awareness Project. “With millions of sufferers remaining undiagnosed, it is critical to raise nationwide awareness about obstructive sleep apnea so that it can be treated with CPAP therapy, which can reduce the risk of cardiovascular death.”

In the context of the ad campaign, the word HEARTS is used as an acronym which names all of the negative health consequences of uncontrolled obstructive sleep apnea. The condition increases the risk of heart failure, elevated blood pressure, atrial fibrillation, resistant hypertension, type 2 diabetes and stroke.

“It is clear that untreated, severe obstructive sleep apnea may have a devastating impact on heart health,” said Dr. Janet B. Croft, senior chronic disease epidemiologist in CDC's Division of Population Health. “Anyone who has symptoms of sleep apnea such as loud snoring in addition to obesity and a heart problem or high blood pressure should discuss their risk for sleep apnea with their doctor.”

Obstructive sleep apnea is characterized by the collapse of the upper airway during sleep, and affects almost 30 million Americans. Obesity, high blood pressure, snoring and fatigue are all risk factors and warning signs of sleep apnea, according to the National Healthy Sleep Awareness Project.


Keywords: Sleep Apnea, Heart Attack, Heart Disease


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.